1 Money-Making Stock Investors Are Sleeping On
ResMed might not be a household name for the average investor, but its portfolio of almost 6,000 patents focused on sleep apnea and respiratory care suggest perhaps it should be. The IP forms an economic moat for ResMed in the medical devices industry, which is massive.
One of the key factors attracting investors to ResMed is the booming sleep apnea devices market, » Read more about: 1 Money-Making Stock Investors Are Sleeping On »
Read More
Is Peloton Finally a Buy?
» Read more about: Is Peloton Finally a Buy? »
Read More
Could This Stock Be the Jewel of Your Portfolio?
In a stock market where technology stocks grab so much attention, a jewelry stock may easily go under the radar. But Signet Jewelers (SIG) has dazzled in more ways than one as you’re about to see.
From its humble Bermudian beginnings in 1950, Signet has grown to about 3,600 jewelry stores and holds the title of the world’s biggest diamond retailer.
» Read more about: Could This Stock Be the Jewel of Your Portfolio? »
Read More
1 Underrated Tech Stock to Beat the Market
The CPaaS, or communication platform as a service, market is seeing tremendous growth. According to Juniper Research, the CPaaS industry could hit the $10 billion revenue mark globally by the end of 2022. And if businesses continue adopting APIs for business-to-customer and customer-to-business interactions, it could reach $35 billion by 2026. One underrated company serving this industry has the potential to beat the market: Twilio (NYSE:TWLO).
» Read more about: 1 Underrated Tech Stock to Beat the Market »
Read More
Why This Doctor Invests In Tesla Weekly?
I met a doctor recently who has been buying up as much Tesla as he can get his hands on. Remarkably he told me that he buys shares of Tesla every single week, accumulating as big a position as he possibly can.
In light of Tesla shares falling this past week after Musk made some almost outlandish predictions –
» Read more about: Why This Doctor Invests In Tesla Weekly? »
Read MoreThe Burst
Billionaire Buys Stake In Gene Therapy Stock
Ultragenyx may not have crossed your radar but it’s already in billionaire Stan Druckenmiller’s portfolio. What has he spotted in this novel therapies for rare and ultra-rare genetic diseases firm that convinced him to take a position?
Its focus on underserved patient populations, deep pipeline of innovative products, and strong track record in obtaining regulatory approvals make it an attractive long-term investment,
» Read more about: Billionaire Buys Stake In Gene Therapy Stock »
Read MoreThe Ivy
The $1 Trillion Buyback Boom, Who’s Spending Most to Boost Their Stock?
In February 2025 alone, corporate America saw an explosion of stock buybacks. More than 160 companies announced fresh repurchase plans—more than double the previous month’s tally. But the real story isn’t just the sheer volume; it’s who is leading the charge.
Goldman Sachs projects that S&P 500 buybacks will hit a record-breaking $1 trillion in 2025,
» Read more about: The $1 Trillion Buyback Boom, Who’s Spending Most to Boost Their Stock? »
Read MoreThe Daily
Don’t Let These 6 Retirement Planning Errors Derail Your Future
It’s estimated that you’ll need at least 75% of your pre-retirement income to enjoy your golden years after you stop working. That can be a daunting challenge when you consider all the planning missteps you could potentially make along the way. However, you can potentially avoid them if you’re aware of the most common retirement planning errors.
» Read more about: Don’t Let These 6 Retirement Planning Errors Derail Your Future »